Navigation Links
FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
Date:7/23/2008

BOSTON, July 23 /PRNewswire/ -- FluoroPharma Inc., a company developing breakthrough molecular imaging agents for the Positron Emission Tomography (PET) market, announced positive Phase I results for BFPET, its novel Fluorine-18 labeled tracer for myocardial perfusion imaging. BFPET is FluoroPharma's second cardiovascular product to complete Phase I clinical development.

BFPET is a PET imaging agent, designed to assess the blood flow in the heart (myocardial perfusion). Myocardial perfusion imaging is a standard test to assess coronary artery disease (CAD), with more than 9 million Americans undergoing the test annually. The Phase I trial, led by Principal Investigator Alan J. Fischman, MD, PhD at the Massachusetts General Hospital, was designed to evaluate safety, distribution and dosimetry of BFPET in 12 healthy subjects following a single dose injection at rest.

"BFPET Phase I data demonstrates that the agent has a favorable dosimetry and pharmacokinetics profile and is well tolerated. All safety endpoints were achieved with no adverse events and no clinically significant changes noted in follow-up clinical and laboratory testing," said Dr. Fischman, Professor of Radiology at Harvard Medical School. "Biodistribution results indicate fast blood clearance, rapid and stable myocardial uptake and high heart to background ratios."

"We are encouraged by the positive initial clinical safety results and look forward to validating BFPET's performance in the next stage of development," said Dr. David Elmaleh, FluoroPharma's founder, Chief Scientific Advisor, and Associate Professor of Radiology at Harvard Medical School. "The high quality cardiac images obtained in this study indicate that new cardiac PET imaging agents can expand the applications of PET beyond the use of FDG (2-18Fluoro-2-deoxy-D-Glucose) in oncology and neurology. With two cardiac agents in clinical development and a third in our pipeline, FluoroPharma hopes to pave the way for cardiovascular PET."

"We are delighted to have reached this important clinical milestone as it addresses the need for innovative agents that draw on the inherently superior resolution of PET imaging compared to SPECT," said Dr. Kundakovic, President of FluoroPharma. "There is tremendous opportunity for BFPET, as a PET alternative in the SPECT dominated myocardial perfusion imaging market. The use of BFPET in conjunction with PET technology holds the promise to better quality CAD diagnosis."

About FluoroPharma

FluoroPharma is a molecular imaging company engaged in the discovery and development of proprietary products for the PET market. FluoroPharma is advancing three proprietary products for assessment of acute and chronic forms of coronary disease. These agents have been designed to rapidly target either the myocardial cells within the heart or inflamed plaques within the coronary arteries. http://www.fluoropharma.com

This release may contain forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements reflect, among other things, management's current expectations, plans and strategies, and anticipated financial results, all of which are subject to known and unknown risks, uncertainties and factors that may cause our actual results to differ materially from those expressed or implied by these forward-looking statements. Many of these risks are beyond our ability to control or predict including the company's need for additional funds, the company's dependence on a limited number of imaging compounds, the early state of the products the company is developing, uncertainties relating to clinical trials and regulatory reviews, competition and dependence on collaborative partners, the company's ability to avoid infringement of the patent rights of others, and the company's ability to obtain adequate patent protection and to enforce these rights. Because of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. Furthermore, forward-looking statements speak only as of the date they are made. FluoroPharma does not undertake any obligation to update or review any such forward-looking information, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE FluoroPharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. FluoroPharma Announces Positive Phase I Safety Results for CardioPET(TM), Coronary Artery Disease (CAD) Imaging Tracer for Positron Emission Tomography (PET)
2. FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... Research and Markets has announced the addition of the ... their offering. ... Cystic fibrosis (CF) is a progressive genetic condition and is the ... regulator (CFTR) gene from both parents. The defective CFTR genes produce ... the buildup of a thick and sticky mucus in the lungs ...
(Date:1/13/2017)... , Jan. 12, 2017  Albertsons Companies proudly ... Commission for Health Care (ACHC) for its specialty ... food and drug chain with this accreditation and ... patients. Accreditation by ACHC reflects Albertsons ... to facilitate a higher level of performance and ...
(Date:1/13/2017)... , Jan. 13, 2017  Biologics Prescribers ... Drug Administration (FDA) for issuing final guidance ... medicines. This policy is an important win ... is essential for pharmacovigilance, patient safety and ... has voiced to FDA, we remain concerned with "random" ...
Breaking Medicine Technology:
(Date:1/15/2017)... ... , ... Whole Health Supply, LLC is announcing the release of an updated version of their ... , The 2017 edition has wide jaws that will accommodate nails up to 4mm ... as diabetics. This handle is reinforced for extra strength when pressing down on dense nails ...
(Date:1/15/2017)... (PRWEB) , ... January 15, 2017 , ... The Gravity ... location in Radnor, Pennsylvania. As construction wraps up on the 14,000+ square foot climbing ... Gravity Vaults sixth location, including three in New Jersey and two in New York. ...
(Date:1/14/2017)... ... January 14, 2017 , ... "TransFreeze Volume 3 is a self animating masking transition which ... Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... frame transition from one clip to the next. , To use “Cut-Out First” ...
(Date:1/13/2017)... ... 2017 , ... With the increasing public preference for chemical-free ... organic alternatives for customers who have grown more conscious about maintaining their health ... activated charcoal products, Moody Zook Chief Executive Officer Nate Ginsburg explained their company’s ...
(Date:1/13/2017)... , ... January 13, 2017 , ... Friday, January 13 ... of the game room, increasing the size of the location to 90,000 square feet. ... 8-hole mini golf course that takes customers on an educational tour of the historic ...
Breaking Medicine News(10 mins):